Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
XLO | US
0.01
1.89%
Healthcare
Biotechnology
30/06/2024
09/03/2026
0.54
0.54
0.57
0.53
Xilio Therapeutics Inc. a clinical-stage biotechnology company discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101 an investigational Fc-enhanced tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs which comprises XTX202 a tumor-activated IL-2; and XTX301 an investigational tumor-activated engineered IL-12 molecule. Xilio Therapeutics Inc. was founded in 2016 and is headquartered in Waltham Massachusetts.
View LessStrength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
32.9%1 month
52.5%3 months
44.3%6 months
48.9%-
-
1.02
0.26
0.10
-0.11
-
-
-64.91M
23.73M
23.73M
-
-622.57
-
-
-130.03
0.68
0.38
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.07
Range1M
0.10
Range3M
0.24
Rel. volume
1.25
Price X volume
299.92K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| INmune Bio Inc | INMB | Biotechnology | 1.31 | 25.98M | -1.50% | n/a | 14.65% |
| HCW Biologics Inc. Common Stock | HCWB | Biotechnology | 0.5926 | 25.86M | -4.43% | n/a | -159.13% |
| PDS Biotechnology Corporation | PDSB | Biotechnology | 0.6851 | 25.23M | 1.81% | n/a | 78.85% |
| Can-Fite BioPharma Ltd | CANF | Biotechnology | 4.08 | 24.87M | -10.33% | n/a | 0.00% |
| Enlivex Therapeutics Ltd | ENLV | Biotechnology | 1.16 | 24.83M | 1.75% | n/a | 2.92% |
| Dyadic International Inc | DYAI | Biotechnology | 0.8 | 23.58M | 4.22% | n/a | 175.64% |
| Edesa Biotech Inc | EDSA | Biotechnology | 7.14 | 23.19M | 9.51% | n/a | 1.35% |
| iBio Inc | IBIO | Biotechnology | 2.5 | 22.84M | -4.21% | n/a | 20.92% |
| Aligos Therapeutics Inc | ALGS | Biotechnology | 7.025 | 22.45M | 0.64% | n/a | 14.63% |
| Cingulate Inc. Common Stock | CING | Biotechnology | 6.85 | 20.85M | 6.53% | n/a | 10.72% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6001 | 11.60M | -5.42% | n/a | 58.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 3.98 | 6.06M | -4.33% | n/a | 204.46% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.47 | 3.75M | -0.67% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.39 | 3.71M | -1.76% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.46 | 1.36M | 2.93% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.008 | 737.72K | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.11 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.02 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 44.28 | 72.80 | Lower Risk |
| Debt to Equity | 0.26 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 23.73M | 3.66B | Emerging |